Market closed
Aligos Therapeutics/$ALGS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aligos Therapeutics
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Ticker
$ALGS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
70
ISIN
US01626L2043
Website
ALGS Metrics
BasicAdvanced
$27M
-
-
-
-
Price and volume
Market cap
$27M
52-week high
$46.80
52-week low
$3.76
Average daily volume
163K
Financial strength
Current ratio
7.558
Quick ratio
7.276
Long term debt to equity
3.767
Total debt to equity
6.762
Management effectiveness
Return on assets (TTM)
-38.74%
Return on equity (TTM)
-60.44%
Valuation
Growth
Revenue change (TTM)
-76.29%
3-year revenue growth (CAGR)
-18.41%
ALGS News
AllArticlesVideos
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
GlobeNewsWire·1 day ago
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
GlobeNewsWire·3 days ago
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aligos Therapeutics stock?
Aligos Therapeutics (ALGS) has a market cap of $27M as of May 09, 2025.
What is the P/E ratio for Aligos Therapeutics stock?
The price to earnings (P/E) ratio for Aligos Therapeutics (ALGS) stock is 0 as of May 09, 2025.
Does Aligos Therapeutics stock pay dividends?
No, Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Aligos Therapeutics dividend payment date?
Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders.
What is the beta indicator for Aligos Therapeutics?
Aligos Therapeutics (ALGS) does not currently have a Beta indicator.